Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria

You may also be interested in...



Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine

U.S. FDA's Center for Biologics Evaluation and Research slapped CSL Biotherapies with a warning letter June 15 for significant objectionable conditions related to current good manufacturing practices at its Victoria, Australia, manufacturing plant

Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine

U.S. FDA's Center for Biologics Evaluation and Research slapped CSL Biotherapies with a warning letter June 15 for significant objectionable conditions related to current good manufacturing practices at its Victoria, Australia, manufacturing plant

CSL Bullish on Immunoglobulins, Bearish On Plasma Pricing

TOKYO - CSL closed its 2010 fiscal year with a mixed bag of results. From gains in its plasma portfolio to disappointments in Gardasil and influenza vaccines, the Melbourne, Australia-based company's 2011 outlook is a combination of caveats and prospects

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel